ROSEWOOD Primary Analysis: Phase II Trial of Zanubrutinib and Obinutuzumab vs Obinutuzumab Alone in R/R Follicular Lymphoma

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Results of the ROSEWOOD trial suggest a favorable risk–benefit ratio for zanubrutinib and obinutuzumab, as indicated by improved ORR, DoR, PFS, and OS compared with obinutuzumab alone and no unexpected safety signals.
Format: Microsoft PowerPoint (.ppt)
File Size: 132 KB
Released: June 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings